Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines

Vaccine

Volumn 31, Issue 46, 2013, Pages 5413-5421

  Kumar, Rajnish ^a   Tuen, Michael ^a   Liu, Jianping ^a   Nàdas, Arthur ^b   Pan, Ruimin ^b   Kong, Xiangpeng ^b   Hioe, Catarina E ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; HIV 1 envelope gp120; Immune complex; N linked glycans; Neutralization; V3 loop; Vaccine

Indexed keywords

CD4 ANTIBODY; CROSS REACTING ANTIBODY; EPITOPE; GLYCAN; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN F(AB) FRAGMENT; MANNOSIDASE INHIBITOR; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; V3 PROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; ARTICLE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

ABS; ANTIBODIES; ANTIBODY; CD4-BINDING SITE OF HIV-1 GP120; CD4BS; DDA; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; HIV-1 ENVELOPE GP120; IMMUNE COMPLEX; MABS; MONOCLONAL ANTIBODIES; MONOPHOSPHORYL LIPID A; MPL; N-LINKED GLYCANS; NABS; NASCN; NEUTRALIZATION; NEUTRALIZING ANTIBODIES; SODIUM THIOCYANATE; V3 LOOP; VACCINE;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIGEN-ANTIBODY COMPLEX; EPITOPES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; MICE, INBRED BALB C; POLYSACCHARIDES;

EID: 84886085760     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.010     Document Type: Article

References (45)

1. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., et al. Diversity considerations in HIV-1 vaccine selection. Science 2002, 296(5577 (June)):2354-2360.
2. Seaman M.S., Janes H., Hawkins N., Grandpre L.E., Devoy C., Giri A., et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 2010, 84(3 (February)):1439-1452.
3. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194(12 (December)):1661-1671.
4. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191(5 (March)):654-665.
5. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F., et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191(5 (March)):654-665.
6. Hioe C.E., Visciano M.L., Kumar R., Liu J., Mack E.A., Simon R.E., et al. The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120. Vaccine 2009, 28(2 (December)):352-360.
7. Visciano M.L., Tuen M., Gorny M.K., Hioe C.E. In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. Virology 2008, 372(2 (March)):409-420.
8. Bou-Habib D.C., Roderiquez G., Oravecz T., Berman P.W., Lusso P., Norcross M.A. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994, 68(9 (September)):6006-6013.
9. Jiang X., Burke V., Totrov M., Williams C., Cardozo T., Gorny M.K., et al. Conserved structural elements in the V3 crown of HIV-1 gp120. Nat Struct Mol Biol 2010, 17(8 (August)):955-961.
10. Agarwal A., Hioe C.E., Swetnam J., Zolla-Pazner S., Cardozo T. Quantitative assessment of masking of neutralization epitopes in HIV-1. Vaccine 2011, 29(39 (September)):6736-6741.
11. Krachmarov C.P., Honnen W.J., Kayman S.C., Gorny M.K., Zolla-Pazner S., Pinter A. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J Virol 2006, 80(14 (July)):7127-7135.
12. Pejchal R., Doores K.J., Walker L.M., Khayat R., Huang P.S., Wang S.K., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334 (November)(6059):1097-1103.
13. Moore J.P., Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996, 70(3 (March)):1863-1872.
14. Li H., Xu C.F., Blais S., Wan Q., Zhang H.T., Landry S.J., et al. Proximal glycans outside of the epitopes regulate the presentation of HIV-1 envelope gp120 helper epitopes. J Immunol 2009, 182(10 (May)):6369-6378.
15. Li Y., Cleveland B., Klots I., Travis B., Richardson B.A., Anderson D., et al. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 2008, 82(2 (January)):638-651.
16. Hioe C.E., Wrin T., Seaman M.S., Yu X., Wood B., Self S., et al. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PloS one 2010, 5(4):e10254.
17. Zolla-Pazner S., Gorny M.K., Nyambi P.N., VanCott T.C., Nadas A. Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV. J Virol 1999, 73(5 (May)):4042-4051.
18. Haigwood N.L., Montefiori D.C., Sutton W.F., McClure J., Watson A.J., Voss G., et al. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol 2004, 78(11 (June)):5983-5995.
19. Herrera C., Spenlehauer C., Fung M.S., Burton D.R., Beddows S., Moore J.P. Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. J Virol 2003, 77(2 (January)):1084-1091.
20. Zhao J., Lai L., Amara R.R., Montefiori D.C., Villinger F., Chennareddi L., et al. Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol 2009, 83(9 (May)):4102-4111.
21. Xiao P., Patterson L.J., Kuate S., Brocca-Cofano E., Thomas M.A., Venzon D., et al. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J Virol 2012, 86(8 (April)):4644-4657.
22. Rawool D.B., Bitsaktsis C., Li Y., Gosselin D.R., Lin Y., Kurkure N.V., et al. Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol 2008, 180(8 (April)):5548-5557.
23. Mikell I., Stamatatos L. Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject. PloS one 2012, 7(11):e49610.
24. Schonning K., Jansson B., Olofsson S., Nielsen J.O., Hansen J.S. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Virology 1996, 218(1 (April)):134-140.
25. Polzer S., Dittmar M.T., Schmitz H., Meyer B., Muller H., Krausslich H.G., et al. Loss of N-linked glycans in the V3-loop region of gp120 is correlated to an enhanced infectivity of HIV-1. Glycobiology 2001 Jan, 11(1):11-19.
26. Doores K.J., Burton D.R. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 2010, 84(20 (October)):10510-10521.
27. Doores K.J., Fulton Z., Huber M., Wilson I.A., Burton D.R. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged. J Virol 2010, 84(20 (October)):10690-10699.
28. McCluskie M.J., Wen Y.M., Di Q., Davis H.L. Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. Viral Immunol 1998, 11(4):245-252.
29. Xu D.Z., Zhao K., Guo L.M., Li L.J., Xie Q., Ren H., et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PloS one 2008, 3(7):e2565.
30. Wen Y.M. Antigen-antibody immunogenic complex: promising novel vaccines for microbial persistent infections. Expert Opin Biol Ther 2009, 9(3 (March)):285-291.
31. Alber D.G., Killington R.A., Stokes A. Solid matrix-antibody-antigen complexes incorporating equine herpesvirus 1 glycoproteins C and D elicit anti-viral immune responses in BALB/c (H-2K(d)) and C3H (H-2K(k)) mice. Vaccine 2000, 19(7-8 (November)):895-901.
32. Roic B., Cajavec S., Ergotic N., Lipej Z., Madic J., Lojkic M., et al. Immune complex-based vaccine for pig protection against parvovirus. J Vet Med B Infect Dis Vet Public Health 2006, 53(1 (February)):17-23.
33. Ivan J., Velhner M., Ursu K., German P., Mato T., Dren C.N., et al. Delayed vaccine virus replication in chickens vaccinated subcutaneously with an immune complex infectious bursal disease vaccine: quantification of vaccine virus by real-time polymerase chain reaction. Can J Vet Res 2005, 69(2 (April)):135-142.
34. Tuen M., Visciano M.L., Chien P.C., Cohen S., Chen P.D., Robinson J., et al. Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation. Eur J Immunol 2005, 35(9 (September)):2541-2551.
35. Kumar R., Tuen M., Li H., Tse D.B., Hioe C.E. Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation. Vaccine 2011, 29(48 (November)):9064-9074.
36. Zolla-Pazner S., Cohen S.S., Krachmarov C., Wang S., Pinter A., Lu S. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology 2008, 372(2 (March)):233-246.
37. Totrov M., Jiang X., Kong X.P., Cohen S., Krachmarov C., Salomon A., et al. Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virology 2010, 405(2 (September)):513-523.
38. Zolla-Pazner S., Kong X.P., Jiang X., Cardozo T., Nadas A., Cohen S., et al. Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J Virol 2011, 85(19 (October)):9887-9898.
39. Liu L., Cimbro R., Lusso P., Berger E.A. Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci USA 2011, 108(50 (December)):20148-20153.
40. Mao Y., Wang L., Gu C., Herschhorn A., Xiang S.H., Haim H., et al. Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat Struct Mol Biol 2012, 19(9 (September)):893-899.
41. White T.A., Bartesaghi A., Borgnia M.J., Meyerson J.R., de la Cruz M.J., Bess J.W., et al. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog 2010, 6(12):e1001249.
42. Malenbaum S.E., Yang D., Cavacini L., Posner M., Robinson J., Cheng-Mayer C. The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J Virol 2000, 74(23 (December)):11008-11016.
43. Binley J.M., Ban Y.E., Crooks E.T., Eggink D., Osawa K., Schief W.R., et al. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 2010, 84(11 (June)):5637-5655.
44. Kwong P.D., Mascola J.R., Nabel G.J. The changing face of HIV vaccine research. J Int AIDS Soc 2012, 15(2):17407.
45. van Montfort T., Eggink D., Boot M., Tuen M., Hioe C.E., Berkhout B., et al. HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation. J Immunol 2011, 187(9 (November)):4676-4685.